Press Releases
Charles River and Aitia Enter Strategic Agreement to Utilize Logica in Discovery Programs for Neurodegenerative Diseases and Oncology
Aitia today announced a strategic agreement with Charles River Labs to utilize Logica in discovery programs for neurodegenerative diseases and oncology. The strategic partnership includes co-development of patient-derived xenograft (PDX) Digital Twins for in vivo oncology research, and an equity investment in Aitia.
Cytoskeleton Genes Underlying Onset and Progression in Multiple Neurodegenerative Disorders Discovered through Aitia’s Digital Twins to be Presented at SfN 2023
Aitia today announced that data from its neurodegenerative disorders Digital Twins will be presented at the Society of Neuroscience (SfN) Conference from November 11-15, 2023 in Washington, D.C.
Prediction of Amyloid PET Positivity from Blood-Based Biomarkers, Proteomics, and Clinical Data Discovered through Aitia’s Digital Twins to be Presented at CTAD 2023
Aitia today announced that the data from its Alzheimer’s Disease Digital Twins will be presented at the Clinical Trials on Alzheimer’s Disease conference (CTAD) from October 24-27 in Boston, MA.
Aitia and Pancreatic Cancer Action Network Partner to Transform De-Identified Multi-Omic Patient Data into Digital Twins to Drive New Discoveries and Improve Patient Outcomes
Aitia today announced a collaboration with the Pancreatic Cancer Action Network (PanCAN), a leading nonprofit in the fight against pancreatic cancer. This strategic collaboration marks a significant milestone for Aitia, reinforcing its commitment to expanding its impact and accelerating the discovery and development of new drugs in pancreatic cancer.
Aitia Appoints Drug R&D Executive Jean-Michel Gries as President & Chief Operating Officer
Aitia, the leader in the development and application of Causal AI and Digital Twins to discover and develop new drugs, today announced the appointment of Dr. Jean-Michel Gries as President & Chief Operating Officer.
Alzheimer’s Disease Mechanistic Pathways Discovered through Aitia’s Digital Twins and in silico Experiments in Causal AI to be Presented at AAIC 2023
Aitia, the leader in the application of Causal AI and Digital Twins to discover and develop new drugs, announced today that data from its Alzheimer’s Disease Digital Twins will be presented at the upcoming Alzheimer’s Association International Conference (AAIC).
Aitia Enters into Multi-Year AI-Driven Drug Discovery and Drug Simulation Collaboration with Servier for Pancreatic Cancer
Aitia, the leader in the development and application of Causal AI and “Digital Twins” to discover and develop new drugs, today announced a collaboration with Servier to create new Gemini Digital Twins to help in the fight against Pancreatic Cancer.
Demonstration of Accurate Screening of Gene Dependency in Multiple Myeloma from Aitia’s Gemini Digital Twins to be Presented at 2023 AACR Annual Meeting
Aitia, the leader in the application of causal AI and “Digital Twins” to discover and develop new drugs, announced today that data from its Multiple Myeloma Digital Twin model will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting.
Aitia and UCB Announce Strategic Drug Discovery Collaboration in Huntington’s Disease
UCB, a global biopharmaceutical company, and Aitia, the leader in the application of Causal AI and “Digital Twins” to discover and develop new drugs, today announced an early drug discovery collaboration focused on the discovery and validation of novel drug targets and drug candidates for Huntington’s disease.
Aitia and G3 Therapeutics Publish Results Identifying New Causal Biomarkers of Atherosclerotic Coronary Artery Disease (ASCAD), the Leading Cause of Morbidity and Mortality Worldwide
G3 Therapeutics, a life sciences company that leverages large-scale multi-omic biological big data to develop life-changing therapeutics and diagnostics, and Aitia, the leader in the application of Causal AI and “Digital Twins” to discover and develop new drugs, today announced results of research that identified new causes of ASCAD.